Liege, Belgium, 25 April 2023 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the invitation to its general shareholders’ meeting that will be held on Thursday May 25 2023 at 2:00 PM (CEST).
The notice for the General Meeting including a description of the formalities to participate in the meeting is available on the website investors.mithra.com.
As referred in the meeting’s invitation published in the Belgian press, the right to participate in the general shareholder’s meeting and to vote is subject to the prior registration of the shares under the shareholder’s name on 11 May 2023 at midnight (CEST) (the “Record Date“), either by way of registration on the company’s share register, or either by way of registration in book entry form in an account held with a settlement institution or a certified account holder, without taking into account the number of shares held by the shareholder at the day of the general meeting. Only persons who are shareholders on the Record Date are entitled to vote at the general meeting.
A certification is delivered to the shareholder by the settlement institution or certified account holder which certifies the number of dematerialized shares registered in its accounts under the name of the shareholder on the Record Date, for which the shareholder has expressed its intention to participate in the general meeting.
The shareholder indicates his willingness to participate in the General Meeting by 19 May 2023 at the latest. This must be done by email to email@example.com, or by mail marked for the attention of Mithra Pharmaceuticals SA, Corporate Secretary, 5, rue Saint-Georges à 4000 Liège.
Right to ask questions
The directors answer questions that are asked by the shareholders, in writing before the meeting, concerning their report or the agenda, in accordance with legal provisions. These questions may be asked prior to the General Meeting by email to the address firstname.lastname@example.org or by mail marked for the attention of Mithra Pharmaceuticals SA, Corporate Secretary, 5, rue Saint-Georges à 4000 Liège. These questions must be received by the Company on 19 May 2023 at the latest.
Further information relating to the abovementioned right and the modalities for exercising them are available on the Company’s website (www.mithra.com).
Any shareholder who wish to vote for that meeting shall be represented by a proxy holder determined by the Company.
Shareholders wishing to be represented must send the completed and signed proxy form to the Company on 19 May 2023 at the latest, by email, fax or mail to Mithra’s headquarter.
Shareholders wishing to vote by mail must send the completed and signed proxy form to the Company on 19 May 2023 at the latest, by email, fax or mail to Mithra’s headquarter.
Further information on the exercise of this right is available on the Company’s website (www.mithra.com). The proxy and voting forms may be obtained on the Company’s website (www.mithra.com) or upon request at the Company’s registered office, or by email to email@example.com.
Shareholders wishing to be represented must comply with the registration and confirmation procedure described above.
All documents concerning the general meeting that are required by law to be made available to shareholders as well as the text of the amended articles of association following the approval of the amendments proposed on the agenda may be consulted on the Company’s website (www.mithra.com) as from 25 April 2023. As from the same date, shareholders have the right to consult these documents on business days and during normal office hours, at the Company’s registered office and/or, upon display of their securities, obtain copies of these documents free of charge.
Requests for copies may also be made, free of charge, by mail (writing) marked for the attention Mithra Pharmaceuticals SA, Corporate Secretary, 5, rue Saint-Georges à 4000 Liège, or by email to firstname.lastname@example.org.
 The form must be signed in writing or electronically, with a qualified electronic signature within the meaning of Regulation (EU) No 910/2014 of the European Parliament and of the Council of 23 July 2014 on electronic identification and trust services for electronic transactions in the internal market and repealing Directive 1999/93/EC, as amended
 See (1)